Please Wait...

CTX-I // C-Terminal Crosslinked Telopeptide of Type I Collagen

Biomarker Therapeutic Areas: 
Biomarker Matrices: 

In bone, type I collagen constitute 90% of the organic matrix. Markers of bone resorption in serum or urine can be used to assess changes in bone resorption in various bone diseases or under treatment (Naylor and Eastell, 2012). Collagen in bone can be isomerized with racemization of the aspartic residues in the CTX telopeptide. The newly formed collagen is α isomerized and β isomerization occurs with aging (Garnero, 2012). In urine, the ratio between native and isomerized CTX can give an estimate of the extent of type I collagen isomerization in bone tissue (Cloos and Fledelius, 2000). Detection of α isomerized fragment in urine is an indicator of newly formed collagen degradation and can be used for detection of bone metastases or Paget’s disease and follow up of treatments. Detection of β isomerized fragments in urine or serum is an indicator of mature bone collagen degradation, like in osteoporosis.

Different manual or automated sandwich immunoassays for CTX-I with α or β isomerization are validated in Bioclinica Lab for measurement in urine or serum matrix. Results in urine are normalized with values of urine creatinine.

ADDITIONAL RESOURCES

Biomarker Menu

Download MENU

Molecular Marker Laboratory Services

Download Brochure

Alzheimer's Disease Biomarker Lab Expertise

Download Info Sheet

Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

We're hiring recent tech grads in #RTP for #pharma sector! Our innov. clinical financial solution gives our client… https://t.co/GHgOfszO0T
bioclinica (3 hours ago)
Great to be @DrugInfoAssn DIA China! Ask us @bioclinica how sponsors & CROs can optimize electronic data capture… https://t.co/TtE4AiLnqY
bioclinica (9 hours ago)
RT @bioclinica: Kinks in the clinical supply chain? Check out how one of our clients is using clinical supply optimization technology for m…
bioclinica (9 hours ago)
RT @bioclinica: Welcoming everyone to KOP for #OCTEast Coast!!
bioclinica (9 hours ago)
Welcoming everyone to KOP for #OCTEast Coast!!
bioclinica (Yesterday)
Case processing is an important aspect of post-marketing drug safety surveillance. Here's a case study showing how… https://t.co/UMYp92Puvc
bioclinica (2 days ago)

Latest Blogs:

Latin America: Benefit from the Right Partner
Removing Risk from Clinical Trial Management System (CTMS) Implementations
Collaboration Between Clinical Operations and the Logistics and Supply Chain Teams is Key to Trial Success
The Value of Protocol Review
CTMS and RBM: Hot Topics at OCT Nordics in Copenhagen